Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Viozan

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Libraries of dibasic compounds designed around the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™) have… 
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
2011
2011
Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were… 
2007
2007
Viozan TM (sibenadet HCI,AR-C68397AA) is a novel dual D 2 dopamine receptor, 132-adrenoceptor agonist that has been investigated… 
  • figure I
  • table 5
2004
2004
1. Sibenadet (Viozan), a dual dopamine D(2)/beta(2)-adrenoceptor agonist, suppresses histamine-induced tachypnoea in the dog by… 
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, developed specifically to… 
  • figure I
  • figure 2
  • figure 3
  • figure 4
2003
2003
Viozan, (Sibenadet HCl, AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator… 
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist that has been investigated… 
2003
2003
The development of novel drugs for the treatment of chronic obstructive pulmonary disease (COPD) poses significant challenges… 
2002
2002
Sensory nerves regulate central and local reflexes such as airway plasma leakage, and cough and their function may be enhanced… 
2001
2001
Abstract. The mechanism by which 2(3H)-benzothiazolone, 4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulphonyl]ethyl]amino]ethyl…